Lv11
38 积分 2023-02-16 加入
543 VIDAR-1: a phase 1/2a master protocol for open-label, multi-centre, single-arm, first-in-human clinical studies of autologous TCR-T therapy targeting mutant KRAS in metastatic or locally advanced PDAC
50分钟前
求助中
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
1个月前
已完结
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
2个月前
已完结
Humanization of T cell–mediated immunity in mice
2个月前
已完结
T-cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial
4个月前
已完结
Antibody development and property analysis of RhBST2 for accurate cell biological and viral research
7个月前
已完结
Antibody development and property analysis of RhBST2 for accurate cell biological and viral research
7个月前
已完结
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
7个月前
已完结
Chapter 6 Cell and Molecular Biology of the Novel Protein Tyrosine‐Phosphatase‐Interacting Protein 51
8个月前
已完结
皖公网安备34019202002308
